| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2019-03-08 |
| タイトル |
|
|
タイトル |
Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Kubota, Yuka
Hatakeyama, Shingo
Tanaka, Toshikazu
Fujita, Naoki
Iwamura, Hiromichi
Mikami, Jotaro
Yamamoto, Hayato
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Ito, Hiroyuki
Yoshikawa, Kazuaki
Sasaki, Atsushi
Kawaguchi, Toshiaki
Ohyama, Chikara
|
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Tohoku Med & Pharmaceut Univ, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Adv Transplant & Regenerat Med, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Adv Transplant & Regenerat Med, Grad Sch Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 著者所属 |
|
|
値 |
Aomori Rosai Hosp, Dept Urol, Hachinohe |
| 著者所属 |
|
|
値 |
Mutsu Gen Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Tsugaru Gen Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Aomori Prefectural Cent Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Dept Urol, Grad Sch Med |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: The clinical impact of neoadjuvant chemotherapy (NAC) on oncological outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC) remains unclear. We investigated the oncological outcomes of platinum-based NAC for locally advanced UTUC.
Results: Of 234 patients, 101 received NAC (NAC group) and 133 did not (Control [Ctrl] group). The regimens in the NAC group included gemcitabine and carboplatin (75%), and gemcitabine and cisplatin (21%). Pathological downstagings of the primary tumor and lymphovascular invasion were significantly improved in the NAC than in the Ctrl groups. NAC for locally advanced UTUC significantly prolonged recurrence-free and cancer-specific survival. Multivariate Cox regression analysis using an inverse probability of treatment weighted (IPTW) method showed that NAC was selected as an independent predictor for prolonged recurrence-free and cancer-specific survival. However, the influence of NAC on overall survival was not statistically significant.
Materials and Methods: A total of 426 patients who underwent radical nephroureterectomy at five medical centers between January 1995 and April 2017 were examined retrospectively. Of the 426 patients, 234 were treated for a highrisk disease (stages cT3-4 or locally advanced [cN+] disease) with or without NAC. NAC regimens were selected based on eligibility of cisplatin. We retrospectively evaluated post-therapy pathological downstaging, lymphovascular invasion, and prognosis stratified by NAC use. Multivariate Cox regression analysis was performed for independent factors for prognosis.
Conclusions: Platinum-based NAC for locally advanced UTUC potentially improves oncological outcomes. Further prospective studies are needed to clarify the clinical benefit of NAC for locally advanced UTUC. |
| 書誌情報 |
ONCOTARGET
巻 8,
号 60,
p. 101500-101508,
発行日 2017-11-24
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1949-2553 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.18632/oncotarget.21551 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 資源タイプ |
|
|
値 |
Article |
oncotarget-101500 (3.9 MB)
